Proteolytic cleavage of urokinase-type plasminogen activator by stromelysin-1 (MMP-3)

被引:60
|
作者
Ugwu, F
Van Hoef, B
Bini, A
Collen, D
Lijnen, HR
机构
[1] Catholic Univ Louvain, Ctr Mol & Vasc Biol, B-3000 Louvain, Belgium
[2] New York Blood Ctr, Lindsley F Kimball Res Inst, Lab Blood Coagulat Biochem, New York, NY 10021 USA
关键词
D O I
10.1021/bi9728708
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Matrix metalloproteinase-3 (MMP-3, or stromelysin-1) specifically hydrolyzes the Glu(143)-Leu(144) peptide bond in 45-kDa single-chain urokinase-type plasminogen activator (scu-PA) and in its two-chain (tcu-PA) derivative, yielding a 17-kDa NH2-terminal domain comprising the u-PA receptor (u-PAR) binding site and a 32-kDa COOH-terminal moiety containing the serine proteinase domain of u-PA. The conversion is completely abolished in the presence of the MMP inhibitors EDTA or 1,10-phenanthroline. Biospecific interaction analysis indicates that binding of MMP-3 occurs through the 32-kDa fragment. The 32-kDa fragment derived from scu-PA (scu-PA-32k) has a specific activity of less than or equal to 500 IU/mg, but it can be activated with plasmin to a two-chain derivative (tcu-PA-32k) with a specific activity of 79 000 IU/mg, tcu-PA and tcu-PA-32k moieties derived from scu-PA-32k by plasmin or from tcu-PA by MMP-3 have comparable amidolytic activities toward the chromogenic substrate S-2444 (k(cat)/K-m of 110 and 160 mM(-1) s(-1), respectively) and similar plasminogen activating activities in a coupled chromogenic substrate assay. Specific binding of the 17-kDa NH2-terminal domain to THP-1 monocytoid cells is completely abolished by competition with scu-PA but is not affected by scu-PA-32k (residual binding of 88 +/- 9% (mean +/- SEM; n = 3) with 25-fold molar excess). Thus, MMP-3 removes a functional NH2-terminal u-PAR-binding domain from u-PA without affecting its enzymatic properties.
引用
收藏
页码:7231 / 7236
页数:6
相关论文
共 50 条
  • [1] The cleavage of pro-urokinase type plasminogen activator by stromelysin-1
    Orgel, D
    Schroder, W
    Hecker-Kia, A
    Weithmann, KU
    Kolkenbrock, H
    Ulbrich, N
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 1998, 36 (09) : 697 - 702
  • [2] Inactivation of plasminogen activator inhibitor-1 by specific proteolysis with stromelysin-1 (MMP-3)
    Lijnen, HR
    Arza, B
    Van Hoef, B
    Collen, D
    Declerck, PJ
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (48) : 37645 - 37650
  • [3] Expression of urokinase-type plasminogen activator, stromelysin 1, stromelysin 3, and matrilysin genes in lung carcinomas
    Bolon, I
    Devouassoux, M
    Robert, C
    Moro, D
    Brambilla, C
    Brambilla, E
    AMERICAN JOURNAL OF PATHOLOGY, 1997, 150 (05): : 1619 - 1629
  • [4] Modulation of cell-associated plasminogen activation by stromelysin-1 (MMP-3)
    Ugwu, F
    Lemmens, G
    Collen, D
    Lijnen, HR
    THROMBOSIS AND HAEMOSTASIS, 1999, 82 (03) : 1127 - 1131
  • [5] Generation of an angiostatin-like fragment from plasminogen by stromelysin-1 (MMP-3)
    Lijnen, HR
    Ugwu, F
    Bini, A
    Collen, D
    BIOCHEMISTRY, 1998, 37 (14) : 4699 - 4702
  • [6] Orally active inhibitors of stromelysin-1 (MMP-3)
    Chapman, KT
    Durette, PL
    Caldwell, CG
    Sperow, KM
    Niedzwiecki, LM
    Harrison, RK
    Saphos, C
    Christen, AJ
    Olszewski, JM
    Moore, VL
    MacCoss, M
    Hagmann, WK
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1996, 6 (07) : 803 - 806
  • [7] Expression of stromelysin-1 (MMP-3), gelatinase B (MMP-9), and plasminogen activator system during fetal calvarial development
    Zeitler, P
    Pahnke, J
    Marx, A
    HISTOPATHOLOGY, 2004, 44 (04) : 360 - 366
  • [8] Bisphosphonates inhibit stromelysin-1 (MMP-3), matrix metalloelastase (MMP-12), collagenase-3 (MMP-13) and enamelysin (MMP-20), but not urokinase-type plasminogen activator, and diminish invasion and migration of human malignant and endothelial cell lines
    Heikkilä, P
    Teronen, O
    Moilanen, M
    Konttinen, YT
    Hanemaaijer, R
    Laitinen, M
    Maisi, P
    van der Pluijm, G
    Bartlett, JD
    Salo, T
    Sorsa, T
    ANTI-CANCER DRUGS, 2002, 13 (03) : 245 - 254
  • [9] Urokinase-type plasminogen activator
    Crippa, Massimo P.
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2007, 39 (04): : 690 - 694
  • [10] Differential regulation of collagenase (MMP-1), stromelysin (MMP-3) and urokinase-type plasminogen-activator (uPA) in cultured human conjunctival and primary pterygium body fibroblasts by inflammatory cytokines.
    Solomon, A
    Li, DQ
    Lee, SB
    Tseng, SCG
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2000, 41 (04) : S8 - S8